Altimmune (ALT) Operating Expenses (2010 - 2026)

Altimmune (ALT) has 17 years of Operating Expenses data on file, last reported at $24.2 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $24.2 million, up 11.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $97.0 million (down 1.28% YoY), and the FY2025 annual result was $94.5 million, down 8.39% from the prior year.
• Operating Expenses slipped to $24.2 million in Q1 2026 per ALT's latest filing, from $28.9 million in the prior quarter.
• Over five years, Operating Expenses peaked at $33.7 million in Q4 2023 and troughed at $18.0 million in Q2 2023.
• A 5-year average of $23.9 million and a median of $23.0 million in 2022 frame the typical range for Operating Expenses.
• On a YoY basis, Operating Expenses climbed as much as 48.5% in 2024 and fell as far as 26.11% in 2024.
• A 5-year view of Operating Expenses shows it stood at $23.0 million in 2022, then soared by 46.45% to $33.7 million in 2023, then retreated by 26.11% to $24.9 million in 2024, then gained by 16.28% to $28.9 million in 2025, then fell by 16.17% to $24.2 million in 2026.
• Business Quant data shows ALT's Operating Expenses at $24.2 million in Q1 2026, $28.9 million in Q4 2025, and $20.9 million in Q3 2025.